哮喘联盟

   摘要
   在过去十年里，治疗一系列疾病(包括高血压、癌症、AIDS、肺结核以及其他感染性疾病)的固定剂量复方制剂的使用呈稳步上升趋势。现有证据显示哮喘或慢性阻塞性肺疾病(COPD)患者同样可从固定剂量复方制剂的使用中获益，包括长效β2受体激动剂与吸入糖皮质激素联合的复方制剂，以及长效β2受体激动剂与长效抗胆碱能药物联合的复方制剂。事实上，目前有许多“三联吸入器”固定剂量复方制剂正在研发，首个三联复方制剂在印度已获批上市。在哮喘或COPD患者治疗中复方制剂(包含具有互补药理作用的药物)的使用也引导了对相同分子中具有两种不同主要药理作用的药物的研发工作，我们称之为“双功能药物”。
   本综述讨论了这类作为哮喘和COPD最新治疗的新双功能药物研发现状，包括双功能支气管扩张剂、双功能支气管扩张剂/抗炎药物以及双功能抗炎药物。
 

（苏楠 审校）
EurRespir J. 2014 Apr 2. [Epub ahead of print]

 

Bifunctional drugs for the treatment of asthma and chronic obstructive pulmonary disease.
 

Page C1, Cazzola M.
 

ABSTRACT
Over the last decade, there has been a steady increase in the use of fixed-dose combinations of drugs for the treatment of a range of diseases, including hypertension, cancer, AIDS, tuberculosis and other infectious diseases. It is now evident that patients with asthma or chronic obstructive pulmonary disease (COPD) can also benefit from the use of fixed-dose combinations, including combinations of a long-acting β2-agonist and an inhaled corticosteroid, and combinations of long-acting β2-agonists and long-acting muscarinic receptor antagonists. In fact, there are now a number of "triple-inhaler" fixed-dose combinations under development, with the first such triple combination having been approved in India. This use of combinations containing drugs with complementary pharmacological actions in the treatment of patients with asthma or COPD has also led to the discovery and development of drugs having two different primary pharmacological actions in the same molecule, which we have called "bifunctional drugs". In this review, we discuss the state of the art of these new bifunctional drugs as novel treatments for asthma and COPD that can be categorised as bifunctional bronchodilators, bifunctional bronchodilator/anti-inflammatory drugs and bifunctional anti-inflammatory drugs.
 

EurRespir J. 2014 Apr 2. [Epub ahead of print]